Overview of QIBA Steering Committee Highlights

- Profile writing speed has exceeded expectations; with approximately 75% complete
- Section authors are using the CT Volumetry and FDG-PET Profiles as templates, with the “spiralizing in” technique
- Remaining obstacles to Profile completion include:
  - Selecting the first use case
  - Quantifying dopamine transporters with iodinated tracers in patients with parkinsonism
    - Quantification will require stronger engagement of device manufacturers and medical physicists
- Expanding the group to other use cases and development of an additional Profile was also discussed
  - Tc-99m applications will also be considered for a whole body Profile in the future
  - Molecular immunology / oncology experts have also expressed an interest in the group’s work
  - Caution voiced regarding overextending the committee focus
- How to make participation easier for device and tracer manufacturers is also under consideration

Profile Strategy Under Consideration:

- After considering dividing into writing groups to address cross-sectional and longitudinal claims, those on the call felt keeping the effort together at this time would be advantageous
  - Separating out the literature analysis work for a longitudinal claim might be reasonable; however, the remainder of the work could remain within one group
  - Dr. Mozley to consult Dr. Obuchowski for her recommendations

Other topics:

- A Profile Editor is needed to collate responses from section authors and maintain version control
- Once a complete draft version of the SPECT Biomarker Committee Profile is complete, the group plans to seek input from pharma and medical physicists, as well as the expertise of antibody and small-molecule drug conjugates
- Current drafts of the Profile are available on the QIBA wiki for review
- Dr. Wahl reminded the group that project proposals for the next round of funding are requested to SPECT BC leadership for consideration: mozley@gmail.com; yuni@umich.edu; jseibyl@mnimaging.com
  - The deadline for proposal submission to RSNA Staff is April 15th
  - Groundwork studies are needed for SPECT

Meeting Feedback Requested:

- In an effort to make the WebEx meetings beneficial for everyone, feedback from participants is requested as follows:
  1. Did everyone have a chance to contribute?
  2. Did anyone feel closed out?
  3. Are there problems sharing the microphone?
  4. Is dead air a problem?
- Please provide suggestions for improving WebEx calls to: mozley@gmail.com; yuni@umich.edu; jseibyl@mnimaging.com
• Sections have been assigned to primary authors as follows:
  o Executive Summary Mozley/Seibyl/whole committee
  o 3.1-3.2 (Pre-delivery, Installation) Device manufacturers/Cella
  o 3.3 (Periodic QA) Dickson/Zimmerman, et al.
  o 3.4-3.5 (Subject selection / handling) Mozley/Seibyl
  o 3.6 (Acquisition) Dewaraja
  o 3.7 (Reconstruction) Frey/Dewaraja
  o 3.8 (Image QA) Dickson/Zimmerman
  o 3.9 (Image Distribution) Klein/Tervé
  o 3.10 (Image Analysis) Miyaoka/Seibyl
  o 3.11 (Image Interpretation) Seibyl, et al.
  o Section 2 Obuchowski / Anne Smith

---

Nuclear Medicine BC Calls:

March:
  • Mar 04:   FDG-PET BC
  • Mar 11:   Amyloid BC
  • Mar 18:   SPECT BC
  • Mar 25:   Combined NM BCs – TBD

SPECT Task Forces: (Tuesdays at 2 pm CT)

  • Feb 23:   Clinical / Literature Review – Dr. Seibyl

March: pending availability of co-chairs
  • Mar 01:   Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
  • Mar 08:   Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
  • Mar 15:   Phantoms / DRO Group – Drs. Dickson and Zimmerman
  • Mar 22:   Clinical / Literature Review – Dr. Seibyl

---

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries. QIBA wiki